Analysts have been eager to weigh in on the Healthcare sector with new ratings on Global Blood Therapeutics (GBT), Aprea Therapeutics (APRE) and Nabriva (NBRV).
Global Blood Therapeutics (GBT)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Global Blood Therapeutics, with a price target of $75.00. The company’s shares closed last Tuesday at $44.23, close to its 52-week low of $36.49.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 22.5% and a 55.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Global Blood Therapeutics with a $78.38 average price target, implying a 71.5% upside from current levels. In a report issued on March 11, Wolfe Research also initiated coverage with a Buy rating on the stock with a $67.00 price target.
See today’s analyst top recommended stocks >>
Aprea Therapeutics (APRE)
In a report released today, Esther Hong from Berenberg Bank maintained a Buy rating on Aprea Therapeutics, with a price target of $10.00. The company’s shares closed last Tuesday at $6.15, close to its 52-week low of $4.66.
According to TipRanks.com, Hong is ranked #4242 out of 7395 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Aprea Therapeutics with a $7.00 average price target.
Nabriva (NBRV)
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Nabriva today. The company’s shares closed last Tuesday at $1.92, close to its 52-week low of $1.52.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 16.0% and a 42.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nabriva with a $6.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
